DUKRW · DUKE Robotics Corp. · Insider Trading

The options vest as follows: 17,867 options vest on the first anniversary of the grant date, and the remaining options vest in quarterly installments over the following 24 months, with 4,466 options vesting at the end of each three-month period and 4,471 options vesting at the end of the final three-month period.

The options vest as follows: one-third (33.33%) of the options vest on the first anniversary of the grant date, one-third (33.33%) vest on the second anniversary of the grant date, and the remaining one-third (33.33%) vest on the third anniversary of the grant date.

The options vest as follows: 9,333 options vest on the first anniversary of the grant date, and the remaining options vest in quarterly installments over the following 24 months, with 2,333 options vesting on each of the first seven quarterly vesting dates and 2,336 options vesting on the final quarterly vesting date.

The options vest as follows: 11,667 options vest on the first anniversary of the grant date, and the remaining options vest in quarterly installments over the following 24 months, with 2,916 options vesting on each of the first seven quarterly vesting dates and 2,921 options vesting on the final quarterly vesting date.

The reported transaction reflects the exercise in full of an option award scheduled to expire on July 13, 2026. The Reporting Person exercised the option prior to its expiration in accordance with the terms of the applicable option agreement.

The reported transaction reflects the exercise in full of an option award scheduled to expire on July 13, 2026. The Reporting Person exercised the option prior to its expiration in accordance with the terms of the applicable option agreement.

The option vests in three equal annual installments beginning on March 10, 2027.

The option vests in three equal annual installments beginning on March 10, 2027.

The option vests in three equal annual installments beginning on March 10, 2027.

The option vests in three equal annual installments beginning on March 10, 2027.

The option vests in three equal annual installments beginning on March 10, 2027.

The option vests in three equal annual installments beginning on March 10, 2027.

50,000 options (the "Option Shares") to purchase common stock, par value $0.0001 per share, of the issuer, at an exercise price of $0.21 per share, were received as compensation for the reporting person's service as the Chief Financial Officer of the issuer, effective as of March 18, 2025 (the "Grant"). The Option Shares associated with the Grant will vest pursuant to three equal installments of 33% at the end of each year. The options expire after six (6) years from the date of grant, and such other terms and conditions set forth in the Company's 2021 Equity Incentive Plan.

. 500,000 options (the "Option Shares") to purchase common stock, par value $0.0001 per share, of the issuer were received as compensation for the reporting person's service as Chief Technology Officer of the issuer pursuant to the consulting agreement, dated March 18, 2025, by and between the Company and Mr. Maor (the "Grant"). The Option Shares associated with the Grant are scheduled to vest on the following schedule: 33% of the options will vest after 12 months and the remaining portion will vest in eight equal installments over eight quarters. The options expire after six (6) years from the date of grant, and such other terms and conditions set forth in the Company's 2021 Equity Incentive Plan.

1,000,000 options (the "Option Shares") to purchase common stock, par value $0.0001 per share, of the issuer, at an exercise price of $0.21 per share, were received as compensation for the reporting person's service as the Chief Executive Officer of the issuer, effective as of March 18, 2025 (the "Grant"). The Option Shares associated with the Grant will vest pursuant to three equal installments of 33% at the end of each year. The options expire after six (6) years from the date of grant, and such other terms and conditions set forth in the Company's 2021 Equity Incentive Plan.

On or about July 14, 2022, pursuant to the terms of a Settlement Agreement dated as of June 17, 2021 (the "Settlement Agreement"), by and among the Reporting Person, the Issuer, Afek Trading Kadosh and Razi Ltd., and Blackhawk Laboratories (the "Plaintiff"), the Reporting Person transferred 157,094 shares of common stock, for no consideration, to the Plaintiff pursuant to the Settlement Agreement.

The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively.

The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively.

The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively.

The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively.

The options shall vest over a three year period, subject to the reporting person's continued service to the company, with 50% of the options to vest on the first anniversary of the grant date, and the balance of 50% of the options to vest in equal parts on the second and third anniversary of the grant date, respectively.

These shares were purchased from the Company in a Private Transaction approved by the Board of Directors at $0.00367 per share pursuant to a Stock Option dated September 1, 2015.

The Company compromised $7,679 of a total advances of $208,309, and exchanged the remaining balance of $200,630 for an 8% Convertible Debenture in the amount of $99,054, with a three year Maturity Date, convertible for 264,850 shares, at a conversion price of $0.3740. The conversion price is subject to reduction in the event of dilutive issuances, and the underlying shares would be increased.

These shares were purchased from the Company in a Private Transaction approved by the Board of Directors at $0.00367 per share.